Profusa Business Summary

Profusa, Inc. (PFSA) is a commercial-stage digital health firm that generates revenue through its proprietary Lumee™ Tissue Oxygen Monitoring platform, utilizing a multi-channel model encompassing direct product sales, service-based fees from contract research organizations (CROs), and strategic licensing agreements. The company operates primarily within the tissue-integrated biosensor and continuous biochemical monitoring segments, targeting high-impact clinical applications such as critical limb ischemia, chronic wound care, and post-operative perfusion. Revenue streams are currently scaling via the January 2026 launch of research-use-only (RUO) offerings and the anticipated Q2 2026 commercial rollout of Lumee™ systems in the European Union. Direct competitors include PetVivo (PETV), Baird Medical Investment (BDMD), and CollPlant Biotechnologies (CLGN); within this group, Profusa occupies a specialized niche as a pioneer of injectable, long-term hydrogel sensors that provide real-time, medical-grade data without the inflammatory response typical of traditional implants. The leadership team is anchored by Chairman and CEO Ben Hwang, Ph.D., whose background includes senior roles at Life Technologies and McKinsey & Company, and Co-founder and Chief Scientific Officer Bill McMillan, a biotech pioneer and former co-founder of Cepheid. Key executives include CFO Fred Knechtel, formerly of Northrop Grumman and Stanley Black & Decker, and Phil Constantinou, an Evernote founding team member serving as Head of Software and Data Science. The company’s governance is supported by a high-profile board, including Lead Independent Director Peter O’Rourke, the former Acting U.S. Secretary of Veterans Affairs, and Director Lauren Chung. Notable institutional support includes a strategic "know-how" partnership with the Mayo Clinic, which maintains a financial interest in the company’s oxygen-sensing technology, and a $100 million funding facility from Ascent Partners Fund LLC that underpins Profusa’s aggressive commercial expansion and digital asset treasury strategy.